SCAFFOLD TECHNOLOGY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On March 19, 2024, Tempo Therapeutics, Inc., a leading innovator in tissue engineering and regenerative medicine, announced the successful completion of a USD 12 million Series A equity fundraising round. Tempo's funding will help the company to improve its breakthrough Microporous-Annealed-Particle (MAP) technology platform and put its synthetic tissue scaffold candidates into clinical trials.
• On February 13, 2024, BIOTRONIK, a leading global medical technology company, announced the CE approval and launch of Freesolve Resorbable Magnesium Scaffold (RMS). This third-generation RMS is designed to provide optimal vascular support while achieving magnesium resorption within 12 months. The new Freesolve RMS is a ground-breaking vascular breakthrough based on reliable clinical evidence.
• In June 2023, The Indian Drugs Controller approved the first indigenously generated tissue engineering scaffold from mammalian organs, an animal-derived Class D Biomedical Device capable of rapidly healing skin wounds at low cost and with minimal scarring. With this, the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), an autonomous institution of the Department of Science and Technology (DST), became India's first institution to develop Class D medical devices that meet all statutory requirements of the Central Drugs Standard Control Organization, Government of India.
• In July 2021, BD, a global leader in medical technology, announced the acquisition of Tepha, Inc., a leading researcher and manufacturer of unique resorbable polymer technology. Tepha's GalaFLEX products are bioresorbable scaffolds used for soft tissue support as well as to heal, elevate, and strengthen deficiencies where weakness or voids exist and material is required to achieve the desired surgical outcome.